Pharmaceutical Technology Transfer

Access to essential medicines in developing countries including Kenya has remained a concern. Past studies have pointed out technology transfer between innovator and local generic manufacturing companies as the possible solution to this problem of access. The current study assessed the viability of technology transfer as a solution to medicines access in Kenya. The study assessed the current situation with regard to medicines access and use of pharmaceutical technology transfer as a tool to bridge the gap in essential medicines access; identified the underlying barriers to pharmaceutical technology transfer and proposed a the lifecycle approach framework for technology transfer in the context of Kenya pharmaceutical industry. The study was supported by literature collected from various online sources to support the identified research problem. The research took a descripto-explanatory design using a combination of qualitative and quantitative methods.

Autorentext

John Muriithi Mwangi trabaja actualmente en Bayer como Jefe de Asuntos Reglamentarios y Garantía de Calidad, responsable de la región de África Central Oriental y Occidental, con sede en Kenia. Anteriormente ha desempeñado diferentes funciones en Farmacovigilancia y Control de Calidad dentro de la Industria Farmacéutica.